<DOC>
	<DOCNO>NCT01425203</DOCNO>
	<brief_summary>The purpose study determine whether Boceprevir ( BOC , SCH 503034 , MK-3034 ) combination Peginterferon Alfa 2-b ( PEG ) plus Ribavirin ( RBV ) [ PEG+RBV=PR ] effective treatment chronic hepatitis C ( CHC ) genotype 1 among Russian population . The primary hypothesis percentage participant achieve sustain virologic response BOC + PR group superior Placebo ( PBO ) + PR group .</brief_summary>
	<brief_title>The Effect Boceprevir Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 ( P08160 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion criterion : body weight ≥40 kg ≤125 kg previously document CHC genotype 1 infection ; must liver biopsy histology consistent CHC etiology cirrhosis present , must ultrasound within 6 month screen visit ( screen Day 1 ) finding suspicious hepatocellular carcinoma ( HCC ) agree use acceptable method contraception partner previously untreated pegylatedinterferon ( either alfa2a alfa2b ) plus RBV fail prior treatment pegylatedinterferon ( either alfa2a alfa2b ) plus RBV Exclusion criterion : coinfected human immunodeficiency virus ( HIV ) hepatitis B virus ( Hepatitis B surface antigen [ HBsAg ] positive ) . require discontinuation previous interferon ribavirin regimen adverse event ( possibly probably relate ) treatment ribavirin within 90 day interferonalpha , base amendment , within 1 month prior screen treatment investigational drug within 30 day screen visit trial evidence decompensated liver disease include , limited , history presence clinical ascites , bleed varix , hepatic encephalopathy diabetic and/or hypertensive clinically significant ocular examination finding clinical diagnosis substance abuse specify drug within specify timeframes know preexist medical condition could interfere participant 's participation completion trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>